A correction may be in store for Arbutus Biopharma Corporation (NASDAQ:ABUS) shares?

As of close of business last night, Arbutus Biopharma Corporation’s stock clocked out at $3.03, up 2.36% from its previous closing price of $2.96. In other words, the price has increased by $+0.0700 from its previous closing price. On the day, 1955730 shares were traded. ABUS stock price reached its highest trading level at $3.0800 during the session, while it also had its lowest trading level at $2.9700.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



To gain a deeper understanding of ABUS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.60 and its Current Ratio is at 4.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.

On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 12.77 while its Price-to-Book (P/B) ratio in mrq is 3.44.

Stock Price History:

Over the past 52 weeks, ABUS has reached a high of $3.22, while it has fallen to a 52-week low of $1.85. The 50-Day Moving Average of the stock is 2.7618, while the 200-Day Moving Average is calculated to be 2.4990.

Shares Statistics:

It appears that ABUS traded 963.46K shares on average per day over the past three months and 1.2M shares per day over the past ten days. A total of 155.60M shares are outstanding, with a floating share count of 116.15M. Insiders hold about 25.66% of the company’s shares, while institutions hold 30.00% stake in the company. Shares short for ABUS as of Jan 30, 2023 were 4.31M with a Short Ratio of 4.05M, compared to 4.74M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 2.74% and a Short% of Float of 3.72%.

Earnings Estimates

As of right now, 5 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of -$0.12 and a low estimate of -$0.15, while EPS last year was -$0.15. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.11 and low estimates of -$0.16.

Analysts are recommending an EPS of between -$0.43 and -$0.47 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.57, with 5 analysts recommending between -$0.46 and -$0.68.

Revenue Estimates

In the current quarter, 5 analysts expect revenue to total $6.17M. It ranges from a high estimate of $7.3M to a low estimate of $5.32M. As of the current estimate, Arbutus Biopharma Corporation’s year-ago sales were $3.21M, an estimated increase of 92.50% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $5.5M, a decrease of -56.30% less than the figure of $92.50% in the same quarter last year. There is a high estimate of $8M for the next quarter, whereas the lowest estimate is $2.8M.

A total of 5 analysts have provided revenue estimates for ABUS’s current fiscal year. The highest revenue estimate was $40.1M, while the lowest revenue estimate was $38.1M, resulting in an average revenue estimate of $38.96M. In the same quarter a year ago, actual revenue was $10.99M, up 254.60% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $21.48M in the next fiscal year. The high estimate is $29.6M and the low estimate is $11.4M. The average revenue growth estimate for next year is down -44.90% from the average revenue estimate for this year.